Sugi Predict

Sugi Predict / Compounds / SCHEMBL371864

SCHEMBL371864

SCHEMBL371864

COc1cc2c(Oc3ccc(N(C(=O)[C@]4(C(N)=O)C[C@H]4C)c4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCNCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 19/20 0.60
▸ AXL P30530 2/20 0.53
▸ PDGFRB P09619 2/20 0.53
▸ KIT P10721 2/20 0.53
▸ PDGFRA P16234 2/20 0.53
▸ FLT1 P17948 2/20 0.53
▸ KDR P35968 2/20 0.53
▸ FLT3 P36888 2/20 0.53
▸ MST1R Q04912 2/20 0.53
▸ PLK4 O00444 1/20 0.53
▸ STK25 O00506 1/20 0.53
▸ CIT O14578 1/20 0.53
▸ AURKA O14965 1/20 0.53
▸ CHUK O15111 1/20 0.53
▸ MUSK O15146 1/20 0.53
▸ EPHB6 O15197 1/20 0.53
▸ MAPK13 O15264 1/20 0.53
▸ MAP3K13 O43283 1/20 0.53
▸ DAPK3 O43293 1/20 0.53
▸ MAP3K7 O43318 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371770 1.00 MET (0.60) METAXLPDGFRBKITPDGFRA
SCHEMBL371939 0.94 MET (0.61) METAXLPDGFRBKITPDGFRA
SCHEMBL372271 0.94 MET (0.61) METAXLPDGFRBKITPDGFRA
SCHEMBL371950 0.92 MET (0.62) METAXLPDGFRBKITPDGFRA
SCHEMBL371704 0.92 MET (0.62) METAXLPDGFRBKITPDGFRA
SCHEMBL371752 0.91 MET (0.49) METAXLPDGFRBKITPDGFRA
SCHEMBL372154 0.90 MET (0.59) METAXLPDGFRBKITPDGFRA
SCHEMBL372555 0.86 MET (0.52) METAXLPDGFRBKITPDGFRA
SCHEMBL372228 0.86 MET (0.52) METAXLPDGFRBKITPDGFRA
SCHEMBL407426 0.86 MET (0.54) METAXLPDGFRBKITPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20110077233-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2011-03-31 — — US claimed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885PDGFRB 30/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885PDGFRB 30/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885PDGFRB 30/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885PDGFRB 30/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885AXL 109/4885PDGFRB 30/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS MET 312/4885AXL 769/4885PDGFRB 1383/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885PDGFRB 90/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885PDGFRB 90/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885PDGFRB 30/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 MET 2/4885AXL 239/4885PDGFRB 80/4885
US-20110077233-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885AXL 241/4885PDGFRB 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.